Cyclerion Therapeutics | 10-Q: Quarterly report
Cyclerion Therapeutics Announced That Regina Graul Has Joined The Company As President, Effective Immediately, Peter Hecht Will Continue To Work As A Strategic Consultant And Board Member; Steps Down From CEO Role
Cyclerion Therapeutics Announced That Regina Graul Has Joined The Company As President, Effective Immediately, Peter Hecht Will Continue To Work As A Strategic Consultant And Board Member; Steps Down
Cyclerion Therapeutics Names Regina Graul President >CYCN
Cyclerion Therapeutics Names Regina Graul President >CYCN
Press Release: Cyclerion Appoints Regina Graul, Ph.D., as President
Cyclerion Appoints Regina Graul, Ph.D., as President -- Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep ex
12 Health Care Stocks Moving In Friday's Intraday Session
GainersNexImmune (NASDAQ:NEXI) stock moved upwards by 540.4% to $11.07 during Friday's regular session. The market value of their outstanding shares is at $11.7 million. Generation Bio (NASDAQ:GBIO) s
Cyclerion Therapeutics: Announces Appointments of Dina Katabi, Ph.D., and Michael Higgins to Bd of Directors >CYCN
Cyclerion Therapeutics: Announces Appointments of Dina Katabi, Ph.D., and Michael Higgins to Bd of Directors >CYCN
Press Release: Cyclerion Strengthens Board of Directors With Experienced Company Builder and Cutting-edge Innovator
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreakin
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersInovio Pharmaceuticals (NASDAQ:INO) shares moved upwards by 33.2% to $0.48 during Tuesday's regular session. The current volume of 13.0 million shares is 535.8% of Inovio Pharmaceuticals's aver
Cyclerion Therapeutics (CYCN.US) directors sold 8 common shares worth approximately $27.16
It was reported on August 12 that according to documents disclosed by the US Securities and Exchange Commission (SEC) on August 11, $Cyclerion Therapeutics (CYCN.US) $ director MCGUIRE TERRANCE sold 8 common shares at an average price of 3.395 US dollars per share on August 9, with a value of about 27.16 US dollars. Image source: SEC's official website What is a statement on changes in shareholding? The SEC requires insiders of listed companies to publicly disclose their securities transactions and shareholding information. When an insider's shareholding changes, according to different circumstances, as needed
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal
Cyclerion Therapeutics (CYCN) said Monday it has acquired a 10% stake in Tisento Therapeutics as part of an asset purchase agreement in which Tisento acquired brain-penetrant stimulators zagociguat an
Tisento Launches With $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved
Stocks That Hit 52-Week Lows On Thursday
 During Thursday, 56 stocks hit new 52-week lows. 52-Week Low Highlights: Bristol-Myers Squibb (NYSE:BMY) was the biggest company in terms of market cap to set a new 52-week low.American Rebel Hold
Stocks That Hit 52-Week Lows On Wednesday
 Wednesday saw 59 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was TC Energy (NYSE:TRP).China SXT Pharmaceuticals
Stocks That Hit 52-Week Lows On Tuesday
 On Tuesday, 56 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Apellis Pharmaceuticals (NASDAQ:APLS)
Cyclerion Regains Compliance With Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. ("Cyclerion" or the "Company") (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq St
TSP, HEPA and CYCN Are Among Mid-day Movers
Cyclerion Reports 1-For-20 Reverse Stock Split, Effective 5 P.m. On May 15
Cyclerion Reports 1-For-20 Reverse Stock Split, Effective 5 p.m. On May 15
Cyclerion Announces Reverse Stock Split
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the "Company", "Cyclerion Therapeutics", "Cyclerion") (NASDAQ:CYCN) announced today that it will effect a reverse stock split of its
Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors
Cyclerion Therapeutics Inc (NASDAQ:CYCN) has agreed to sell two of its assets - zagociguat (formerly CY6463) and CY3018, to a new private company ("NewCo") formed by certain current Cyclerion sharehol
Cyclerion Therapeutics to Sell Zagociguat, CY3018 Assets to New Private Company
Cyclerion Therapeutics (CYCN) said late Thursday it entered into a definitive agreement with a new private company, created by certain current Cyclerion shareholders and new investors, to sell soluble
No Data